Welcome to our dedicated page for Recursion Pharmaceuticals SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) provides access to the company’s official regulatory disclosures as a clinical-stage TechBio and biotechnology issuer. These documents offer detailed information about Recursion’s financial condition, governance, capital markets activity and key corporate events related to its Recursion OS platform and drug development programs.
Investors can review current reports on Form 8-K, where Recursion reports material events such as quarterly financial results, leadership transitions, collaboration milestones and equity issuances. Recent 8-K filings describe items including second and third quarter financial results, the appointment of a new Chief Executive Officer and President with the prior CEO becoming Chair of the Board, milestone payments from collaborations, and unregistered sales of equity securities connected to acquisitions and license arrangements.
Through its registration statements and prospectus supplements filed under its automatic shelf registration on Form S-3ASR, Recursion documents offerings and resale registrations for shares issued in connection with agreements such as a master license with Tempus AI, Inc. and a membership interest purchase agreement involving a joint venture for an ENPP1 program. These filings outline the number of shares involved, transaction structure and reliance on exemptions from registration for initial issuances.
Users of this page can also monitor filings related to corporate governance and stockholder matters, such as annual meeting results and advisory votes, as well as information about independent auditor ratification. Together with annual reports on Form 10-K and quarterly reports on Form 10-Q, which are accessible through EDGAR, these filings form a comprehensive record of RXRX’s regulatory history.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that explain the significance of key filings. This helps readers quickly interpret lengthy documents such as 10-K and 10-Q reports, understand the implications of Form 8-K disclosures, and track any insider-related or equity issuance activity that may be relevant when evaluating Recursion Pharmaceuticals.
Recursion Pharmaceuticals (RXRX) CEO and director reported a Form 4 for 10/23/2025. He converted 100,000 shares of Class B into Class A at $0 and sold 100,000 Class A shares at
Following these transactions, he directly owned 954,229 Class A shares. The filing also lists remaining Class B holdings and vested/unvested stock options.
Insider transactions at Recursion Pharmaceuticals (RXRX): The CEO and director executed multiple transactions on
The filing also lists multiple outstanding stock options totaling significant potential dilution (options for ~3.2M Class A shares listed under different strike prices and vesting schedules) and indirect holdings via LLCs and a family trust. The sale, acquisition and gift were made under the disclosed trading plan and executed on the same date.
Recursion Pharmaceuticals, Inc. (RXRX) filed a Form 144 notice reporting a proposed sale of 100,000 Class A shares through Fidelity Brokerage, with an aggregate market value of
The filing also discloses multiple recent sales by related parties during the past three months: combined transactions on
Dean Y. Li, a director of Recursion Pharmaceuticals, Inc. (RXRX), acquired 1,961 shares of Class A common stock on 10/01/2025 at a reported price of $0 under the company’s Outside Director Compensation Policy. After the issuance, Mr. Li directly beneficially owns 1,238,528 shares. The filing also discloses indirect holdings: 1,422,048 shares held by the Dean Y. Li Revocable Trust, 136,981 shares held by the Dean Y. Li GRAT, and 421,000 shares held by the Dean Y. Li 2021 Family Trust. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Dar Zavain, a director of Recursion Pharmaceuticals (RXRX), reported acquiring 2,941 shares of Class A common stock on 10/01/2025. The shares were issued $0 under the issuer's Outside Director Compensation Policy. After the transaction, the reporting person beneficially owned 138,758 shares. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 10/03/2025. This filing discloses routine director compensation in equity form.
Christopher Gibson, Chief Executive Officer and Director of Recursion Pharmaceuticals (RXRX), reported transactions dated 09/25/2025. The report shows the acquisition and simultaneous disposition of 100,000 shares of Class A common stock: a conversion/acquisition recorded at $0 and a sale of 100,000 shares at $4.76 per share, reducing his direct beneficial ownership of Class A shares from 1,054,229 to 954,229. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan adopted May 12, 2025. The report also lists indirect holdings through LAHWRAN-3 LLC, LAHWRAN-4 LLC and the Gibson Family Trust, and multiple outstanding stock options and convertible Class B shares that are convertible one-for-one into Class A shares. The form is signed by an attorney-in-fact on 09/26/2025.
Recursion Pharmaceuticals, Inc. (RXRX) Form 144 filed reporting a proposed sale of 100,000 Class A shares through Fidelity Brokerage Services with an approximate aggregate market value of $476,000, with an approximate sale date of 09/25/2025 on NASDAQ. The filing states the shares were originally acquired as Founders Shares on 09/01/2016 and were issued as compensation. The notice also discloses prior sales by related parties during the past three months totaling 817,875 Class A shares for gross proceeds of $3,386,380.00. The signer represents no undisclosed material adverse information exists and includes the standard attestation language required under Rule 144.
Recursion Pharmaceuticals insider transaction: The company's Chief Financial Officer reported a non-derivative transaction in the company's Class A common stock. The filing shows 7,057 shares were withheld as part of net settlement of restricted stock units to satisfy tax withholding at an average price of $4.83 per share, leaving the reporting person with 804,169 shares beneficially owned following the transaction. The filing identifies the transaction as an issuer withholding related to equity compensation rather than an open-market sale.
Form 144 notice for Recursion Pharmaceuticals, Inc. (RXRX) reporting a proposed sale of 100,000 Class A shares through Fidelity Brokerage Services on 09/10/2025 with an aggregate market value of $471,000. The filing shows these shares were acquired as Founders Shares on 09/01/2016 and listed as compensation with 100,000 units subject to sale.
The filing also discloses securities sold in the past three months by related parties: Christopher C. Gibson sold 500,000 shares on 08/11/2025 for $2,640,000 and 100,000 shares on 08/26/2025 for $484,000; Gibson Family Trust sold 17,875 shares on 08/11/2025 for $94,380; Lahwran-3 LLC sold 100,000 shares on 08/11/2025 for $528,000. The filing lists 427,312,960 Class A shares outstanding.
Recursion Pharmaceuticals amended its Form 8-K to report issuance and registration of contingent consideration tied to its ENPP1 JV acquisition. The company completed a GLP toxicology study milestone and on August 27, 2025 issued 2,397,023 Contingent Shares at a per-share price of $5.2148 (calculated from the $12,500,000 milestone). Earlier, on July 8, 2025 the company issued 1,457,952 Initial Shares as part of the Membership Interest Purchase Agreement that made ENPP1 JV an indirect wholly-owned subsidiary. Recursion also filed a prospectus supplement to register the 2,397,023 Contingent Shares for resale and attached a legal opinion from Wilson Sonsini regarding the legality of the shares.